Serometrix LLC | Structured specifically for collaboration and outlicense
With its asset-centric business model, Serometrix is structured to facilitate drug discovery and development collaborations.
Our early stage collaborative business model can optimize resources, while helping our partners to lower risk and shorten development times for high value therapeutic programs.
Serometrix is leveraging its proprietary Dynamic Discovery Platformsm to help solve industry pipeline challenges by developing a solid understanding of allosteric and induced fit interface biochemistry. This product based development strategy is providing complex solutions to previously intractable targets of high commercial value. These solutions yield families of compounds with strong IP that are partnered at an early stage for collaborative development.
Our platform is well positioned to provide value in the following therapeutic areas:
Drug Development Partnerships & Collaborations
Allosteric Drug Discovery
University of Strathclyde, Glasgow, UK
PCSK9 Small Molecule Inhibitors – Licensed